Kinetics of plasma cfDNA predicts clinical response in non-small cell lung cancer patients
| Autor: | Effie Ho, Paul Okunieff, Hui Xu, Michael Y. Sha, Jianwei Lu, Chenchen Li, Xiaorong Zhou, Ping Ding, Daniel Y. Li, Aiguo Zhang, Zhao Zhang, Haiyan Meng, Ronglei Li, Jinwei Du |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
Oncology Lung Neoplasms medicine.medical_treatment Biomarkers Pharmacological Prognostic markers Plasma Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols Multidisciplinary Middle Aged Prognosis Progression-Free Survival Tumor Burden Plasma.cfDNA medicine.anatomical_structure Cohort Carcinoma Squamous Cell Adenocarcinoma Medicine Female Cell-Free Nucleic Acids medicine.drug Adult medicine.medical_specialty Bevacizumab Science Predictive markers Antibodies Monoclonal Humanized Article Disease-Free Survival Internal medicine Biomarkers Tumor medicine Carcinoma Humans Liquid biopsy Lung cancer Protein Kinase Inhibitors Aged Retrospective Studies Chemotherapy Lung business.industry Cancer medicine.disease Kinetics Regimen business Non-small-cell lung cancer |
| Zdroj: | Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021) Scientific Reports |
| ISSN: | 2045-2322 |
| Popis: | Background: Tyrosine Kinases Inhibitors (TKIs), VEGF/VEGF receptor inhibitors (VEGFIs, bevacizumab) and immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced cancer including non-small-cell lung cancer (NSCLC). Cell-free DNA (cfDNA) has been adapted as a convenient liquid biopsy that reflects characteristics of the status of both the primary and metastatic tumors, assisting in personalized medicine. This study aims to evaluate the utility of cfDNA as a prognostic biomarker and efficacy predictor of chemotherapy with or without these precision therapies in NSCLC patients. Methods: Peripheral cfDNA levels were quantified in 154 patients with NSCLC before (baseline) and after (post-chemotherapy) the first target cycle of chemotherapy. These patients were divided into four subgroups receiving chemotherapy only, chemotherapy plus TKIs, chemotherapy plus VEGFIs, and chemotherapy plus immune checkpoint inhibitors (ICIs), respectively. The correlations of cfDNA with tumor burden, clinical characteristics, progression-free survival (PFS), objective response ratio (ORR), and therapy regimens were analyzed. Results: Baseline cfDNA, but not post-chemotherapy, positively correlates with tumor burden. cfDNA Ratio (post-chemotherapy/baseline) well distinguished responsive individuals (CR/PR) from non-responsive patients (PD/SD). Additionally, cfDNA Ratio was found to be negatively correlated with PFS in lung adenocarcinoma (LUAD), but not in lung squamous-cell carcinoma (LUSC). LUAD patients with low cfDNA Ratio benefit significantly including prolonged PFS and improved ORR, compared with those with high cfDNA Ratio. When stratified by therapy regimen, the predictive value of cfDNA Ratio is significant in patients with chemotherapy plus VEGFIs. Conclusion: The kinetics of plasma cfDNA during the chemotherapy may function as a prognostic biomarker and efficacy predictor for NSCLC patients. Funding Statement: None Declaration of Interests: None. Ethics Approval Statement: All participants signed the informed consent agreement. The study was approved by the clinical research ethics committee of the Jiangsu Cancer Hospital and was conducted following the Declaration of Helsinki. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|